Evidence map›Paper›PMID 30125366›Full record

ArticlePhotochemistry and photobiology2019

Nanolipid Formulations of Benzoporphyrin Derivative: Exploring the Dependence of Nanoconstruct Photophysics and Photochemistry on Their Therapeutic Index in Ovarian Cancer Cells.

Girgis Obaid, Wendong Jin, Shazia Bano, David Kessel, Tayyaba Hasan

Open access · bronzeAbstract read
In one paragraph

Article in Photochemistry and photobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 59 citations in OpenAlex.

  1. The clinical ionizable lipid SM-102 enhances photochemical immunogenic cell death by verteporfin-conjugated liposomes and improves survival in vivo.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Targeting tumor angiogenesis and metabolism with photodynamic nanomedicine.Frontiers in cell and developmental biology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. A Physiochemical,ACS applied bio materials · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Girgis ObaidWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-9452-4467
Wendong JinWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Shazia BanoWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
David KesselDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Harvard University · USWayne State University · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Vinay Chandrasekhara · 2001 to 2026
$27.9M
Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Optical imaging guided resection and photodynamic therapy of glioma with targeted photoactivable agentsR21CA220143 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2017 to 2019
$390k
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsK99CA215301 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI OBAID, GIRGIS · 2018 to 2019
$358k
Bullock-Wellman FellowshipChina Scholarship CouncilNCI NIH HHS K99 CA215301NCI NIH HHS P01 CA084203NCI NIH HHS R01 CA156177NCI NIH HHS R01 CA160998NCI NIH HHS R21 CA220143
6 · The paper itself

Abstract

With the rapidly emerging designs and applications of light-activated, photodynamic therapy (PDT)-based nanoconstructs, photonanomedicines (PNMs), an unmet need exists to establish whether conventional methods of photochemical and photophysical characterization of photosensitizers are relevant for evaluating new PNMs in order to intelligently guide their design. As a model system, we build on the clinical formulation of benzoporphyrin derivative (BPD), Visudyne

Indexed as

Photochemical ProcessesCell Line, TumorFemaleHumansLipidsNanoparticlesOvarian NeoplasmsPorphyrinsLipidsPorphyrins

Identifiers

PMID30125366
PMCPMC6347486
OpenAlexW2888027660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.